Compare BAFN & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | ANIK |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 200.9M |
| IPO Year | 2021 | 1996 |
| Metric | BAFN | ANIK |
|---|---|---|
| Price | $6.16 | $21.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 85.7K | ★ 95.2K |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | N/A | $7.82 |
| Revenue Next Year | N/A | $5.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.26 | $9.01 |
| 52 Week High | $9.56 | $22.88 |
| Indicator | BAFN | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 56.57 |
| Support Level | $4.65 | $20.13 |
| Resistance Level | $7.02 | $22.70 |
| Average True Range (ATR) | 0.56 | 0.65 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 45.13 | 70.15 |
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.